AMSTERDAM--(BUSINESS WIRE)--NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces it ...
Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results